Original ContributionsDysplasia as a predictive marker for invasive carcinoma in Barrett esophagus: A follow-up study based on 138 cases from a diagnostic variability study
Section snippets
Materials and methods
From a series of 250 cases that were used to comprehensively test established criteria for grading dysplasia in BE, we obtained follow-up information on 138 patients.28 An attempt was made to obtain follow-up information on all 250; adequate information was available on 138. Briefly, each of 10 participants from 10 institutions contributed slides, all of which were reviewed by 12 observers (2 reviewers did not contribute cases). Each contributor was instructed to supply slides from the initial
Results
Among the 138 patients with clinical follow-up, there were 100 men (72%) and 38 women ranging in age from 9 to 85 years (mean and median, 61 and 63 years, respectively). There were 2 pediatric cases among the lesions with follow-up, 1 from a 9-year-old and 1 from a 17-year-old. Race was known in 85 patients; of these, 83 were white, 1 was black, and 1 was Hispanic.
The submitting diagnoses included 44 cases with no dysplasia, 22 cases indefinite for dysplasia (IND), 26 LGD, 33 HGD, and 13
Discussion
It has been estimated that between 4% and 15% of patients with gastroesophageal reflux disease who undergo endoscopy have BE.36 Given their risk for developing esophageal adenocarcinoma, a risk that has been estimated to be up to 125 times greater than that of the general population,24, 25, 26 most patients are followed up by regular endoscopy and biopsy once a diagnosis of BE is established. The morphologic recognition of dysplasia is the most widely used marker of increased cancer risk, and
References (39)
- et al.
Clinical implications of p53 gene mutation in the progression of Barrett's epithelium to invasive esophageal cancer
Am J Surg
(1994) - et al.
Barrett's esophagus. Correlation between flow cytometry and histology in detection of patients at risk for adenocarcinoma
Gastroenterology
(1987) - et al.
Observer variation in the diagnosis of dysplasia in Barrett's esophagus
Hum Pathol
(1988) - et al.
Reproducibility of the diagnosis of dysplasia in Barrett esophagus: A reaffirmation
Hum Pathol
(2001) - et al.
Prospective multivariate analysis of clinical, endoscopic, and histological factors predictive of the development of Barrett's multifocal high-grade dysplasia or adenocarcinoma
Am J Gastroenterol
(1999) - et al.
An endoscopic biopsy protocol can differentiate high-grade dysplasia from early adenocarcinoma in Barrett's esophagus
Gastroenterology
(1993) - et al.
Dysplasia in inflammatory bowel disease: Standardized classification with provisional clinical applications
Hum Pathol
(1983) - et al.
Low incidence of significant dysplasia in a successful endoscopic surveillance program of patients with ulcerative
Gastroenterology
(1995) - et al.
Cancer surveillance in ulcerative colitis
Gastroenterology
(1991) - et al.
Increased expression of the cyclin D1 gene in Barrett's esophagus
Cancer Epidemiol Biomarkers Prev
(1996)
Molecular analysis of the TP53 gene in Barrett's adenocarcinoma
Hum Mutat
Allelic loss of 9p21 and mutation of the CDKN2/p16 gene develop as early lesions during neoplastic progression in Barrett's esophagus
Oncogene
Evolution of neoplastic cell lineages in Barrett oesophagus
Nat Genet
17p allelic deletions and p53 protein overexpression in Barrett's adenocarcinoma
Cancer Res
Clonal ordering of 17p and 5q allelic losses in Barrett dysplasia and adenocarcinoma
Proc Natl Acad Sci U S A
p53 gene mutations in Barrett's epithelium and esophageal cancer
Cancer Res
p53 protein expression in Barrett's adenocarcinoma: A frequent event with no prognostic significance
Histopathology
Expression of c-erbB-2 oncogene product in Barrett's adenocarcinoma: Pathological and prognostic correlations
J Clin Pathol
Barrett's mucosa. From metaplasia... to cancer
Gastroenterol Clin Biol
Cited by (268)
Barrett's Esophagus and Associated Dysplasia
2024, Gastroenterology Clinics of North AmericaBarrett's esophagus indefinite for dysplasia carries a definite risk of neoplasia
2021, Gastrointestinal EndoscopyRisk of progression in Barrett's esophagus indefinite for dysplasia: a systematic review and meta-analysis
2020, Gastrointestinal Endoscopy